Methamphetamine-related emergency department utilization and cost

Academic Emergency Medicine

Volumn 15, Issue 1, 2008, Pages 23-31

  Hendrickson, Robert G ^a,b,d   Cloutier, Robert ^a,b,c   McConnell, K John ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Oregon Poison Center   (United States)

Author keywords

Amphetamine; Cost; Cost analysis utilization; Emergency medicine; Methamphetamine

Indexed keywords

METHAMPHETAMINE;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; DEMOGRAPHY; DENTAL CARE; DRUG DEPENDENCE; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL COST; HUMAN; INJURY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SKIN DISEASE; SKIN INFECTION; STANDARDIZATION; TOOTH DISEASE; UNITED STATES; DRUG ABUSE; ECONOMICS; EMERGENCY HEALTH SERVICE; ETHNIC GROUP; HOSPITAL CHARGE; PATIENT; SEX RATIO; STATISTICS; UTILIZATION REVIEW;

ADULT; AMPHETAMINE-RELATED DISORDERS; EMERGENCY SERVICE, HOSPITAL; ETHNIC GROUPS; FEMALE; HOSPITAL CHARGES; HUMANS; INSURANCE, HEALTH; MALE; MEDICALLY UNINSURED; METHAMPHETAMINE; OREGON; PROSPECTIVE STUDIES; SEX DISTRIBUTION; UTILIZATION REVIEW;

EID: 44449143667     PISSN: 10696563     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1553-2712.2007.00006.x     Document Type: Article

References (44)

1. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Results From the 2004 National Survey on Drug Use and Health: National Findings (Office of Applied Studies), NSDUH Series H-28, DHHS Publication No. SMA 05-4062. Rockville, MD: 2005. Available at: http://www.drugabusestatistics. samhsa.gov/. Accessed Nov 27, 2007.
2. Richards JR, Bretz SW, Johnson ED, Turnipseed SD, Brofeldt BT, Derlet RW. Methamphetamine abuse and emergency department utilization. West J Med. 1999; 170:198-202.
3. Derlet RW, Rice P, Horowitz BZ, Lord R. Amphetamine toxicity: experience with 127 cases. J Emerg Med. 1989; 7:157-61.
4. Department of Justice, Drug Enforcement Administration, Oregon State Fact Sheet, 2007. Available at: http://www.usdoj.gov/dea/pubs/states/oregon.html. Accessed Apr 2, 2007.
5. Hendrickson RG, Horowitz BZ, Norton RL, Notenboom H. " Parachuting" meth: a novel delivery method for methamphetamine and delayed-onset toxicity from "body stuffing." Clin Toxicol. 2006; 44(4):379-82.
6. Richards JR, Johnson EB, Stark RW, Derlet RW. Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am J Emerg Med. 1999; 17(7):681-5.
7. Richards JR, Derlet RW, Duncan DR. Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J Emerg Med. 1998; 16(4):567-73.
8. Sheridan J, Bennett S, Coggan C, Wheeler A, McMillan K. Injury associated with methamphetamine use: A review of the literature. Harm Reduction J. 2006; 3:14.doi:10.1186/1477-7517-3-14.
9. Ellinwood E. Assault and homicide associated with amphetamine abuse. Am J Psychiatry. 1971; 127:90-5.
10. Yui K, Ikemoto S, Ishiguro T, Goto K. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis and schizophrenia. Ann NY Acad Sci. 2000; 914:1-12.
11. Yui K, Ishiguro T, Goto K, et al. Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosis. Ann NY Acad Sci. 2000; 914:292-302.
12. Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis. 2000; 30:579-91.
13. Packe GE, Garton MJ, Jennings K. Acute myocardial infarction caused by intravenous amphetamine abuse. Br Heart J. 1990; 64:23-4.
14. Furst SR, Fallon SP, Reznik GN, Shah PK. Myocardial infarction after inhalation of methamphetamine. N Engl J Med. 1990; 323:1147-8.
15. Ragaland AS, Ismail Y, Arsura EL. Myocardial infarction after amphetamine use. Am Heart J. 1993; 125:247-9.
16. Bashour TT. Acute myocardial infarction resulting from amphetamine abuse: a spasm-thrombus interplay? Am Heart J. 1994; 128:1237-9.
17. Farnsworth TL, Brugger CH, Malters P. Myocardial infarction after intranasal methamphetamine. Am J Health Syst Pharm. 1997; 54:586-7.
18. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med. 2003; 24:369-73.
19. Burgess JL. Phosphine exposure from a methamphetamine laboratory investigation. Clin Toxicol. 2001; 39(2):165-8.
20. Santos AP, Wilson AK, Hornung CA, Polk HC Jr, Rodriguez JL, Franklin GA. Methamphetamine laboratory explosions: A new and emerging burn injury. J Burn Care Rehabil. 2005; 26:228-32.
21. Ohta K, Mori M, Yoritaka A, Okamoto K, Kishida S. Delayed ischemic stroke associated with methamphetamine use. J Emerg Med. 2005; 28(2):165-7.
22. McGee SM, McGee DN, McGee MB. Spontaneous intracerebral hemorrhage related to methamphetamine abuse: Autopsy findings and clinical correlation. Am J Forensic Med Pathol. 2004; 25:334-7.
23. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005; 100:1320-9.
24. Hando J, Top L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend. 1997; 47:105-13.
25. Shaner JW, Kimes N, Saini T, Edwards P. "Meth mouth": rampant caries in methamphetamine abusers. AIDS Patient Care STDs. 2006; 20:146-50.
26. Richards JR, Brofeldt BT. Patterns of tooth wear associated with methamphetamine use. J Periodontol. 2000; 71:1371-4.
27. Elixhauser A, Steiner C, Palmer L. Clinical Classifications Software (CCS). U.S. Agency for Healthcare Research and Quality. Available at: http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp. Accessed Dec 1, 2006.
28. Elixhauser A, Steiner CA, Whittington C, McCarthy E. Clinical Classifications for Health Policy Research: Hospital Inpatient Statistics, 1995. Healthcare Cost and Utilization Project, HCUP 3 Research Note. Rockville, MD: Agency for Health Care Policy and Research; 1998. AHCPR Pub. No. 98-0049.
29. Krauss NA, Kass B. Comparison of Household and Medical Provider Reports of Medical Conditions (Paper presented at Joint Statistical Meetings, Indianapolis, Indiana), 2000.
30. Cohen JW, Krauss NA. Spending and service use among people with the fifteen most costly medical conditions, 1997. Health Aff. 2003; 22(2):129-38.
31. Florin SM, Kuczenski R, Segal DS. Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment. Brain Res. 1994; 654:53-62.
32. Kuczenski R, Segal DS. Differential effects of amphetamine and dopamine uptake blockers (cocaine, nomifensine) on caudate and accumbens dialysate dopamine and 3-methoxytyramine. J Pharmacol Exp Ther. 1992; 262(3):1085-94.
33. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2004: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-28, DHHS Publication No. (SMA) 06-4143, Rockville, MD: 2006. Available at: http://DAWNinfo.samhsa.gov/. Accessed Nov 27, 2007.
34. Hendrickson RG, Spivak LS. Methamphetamine. Emerg Med Reports. 2006; 27(18):209-24.
35. Logan BK. Methamphetamine and driving impairment. J Forensic Sci. 1996; 41:457-64.
36. Rhodus NI, Little JW. Methamphetamine abuse and "meth mouth." NW Dentistry. 2005; 84:1-17.
37. Saini T, Edwards PC, Kimmes NS, Carroll LR, Shaner JW, Dowd FJ. Etiology of xerostomia and dental caries among methamphetamine abusers. Oral Health Prev Dent. 2005; 3:189-95.
38. Howe AM. Methamphetamine and childhood and adolescent caries [letter]. Austral Dent J. 1995; 40:340.
39. DiCugno F, Perec CJ, Tocci AA. Salivary secretion and dental caries: Experience in drug addicts. Arch Oral Biol. 1981; 26:363-7.
40. Stout PR, Klette KL, Horn CK. Evaluation of ephedrine, pseudoephedrine, and phenylpropanolamine concentrations in human urine samples and a comparison of the specificity of DRI amphetamines and Abuscreen online (KIMS) amphetamines screening immunoassays. J Forensic Sci. 2004; 49(1):160-4.
41. Poklis A, Moore KA. Response of EMIT amphetamine immunoassays to urine desoxyephedrine following Vicks inhaler use. Ther Drug Monit. 1995; 17(1):89-94.
42. D'Nicuola J, Jones R, Levine B, Smith ML. Evaluation of six commercial amphetamine and methamphetamine immunoassays for cross-reactivity to phenylpropanolamine and ephedrine in urine. J Anal Toxicol. 1992; 16(4):211-3.
43. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS). Highlights - 2005. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-36, DHHS Publication No. (SMA) 07-4229, Rockville, MD, 2006.
44. United States Department of Justice, Office of Justice Programs, National Institute of Justice. 2000 Arrestee Drug Abuse Monitoring (ADAM): Annual Report. Washington, DC: Department of Justice, April 2003.